<DOC>
	<DOCNO>NCT00002261</DOCNO>
	<brief_summary>To determine physiological immunological response healthy HIV seronegative adult volunteer vaccinate ) HIVAC-1e ( vaccinia-HIV ) vaccine express envelope glycoprotein HIV b ) Wyeth smallpox vaccine . The parameter study include : 1 . The course physiological response vaccination , include ( ) lesion development , progression , resolution ; ( b ) physiological change temperature , malaise , itch site , etc . ( c ) observable AE . 2 . The appearance , identity , quantity , duration humoral antibody HIV vaccinia virus . 3 . The appearance , identity , quantity , duration cell-mediated immunity HIV vaccinia virus . 4 . The adequacy procedure use special dress contain viral shed vaccination site . 5 . The safety , humoral cellular immune response booster injection recombinant subunit gp160 vaccine ( MicroGeneSys ) HIVAC-1e recipient .</brief_summary>
	<brief_title>A Comparative Phase I Clinical Study HIVAC-1e Smallpox ( Vaccinia ) Vaccines Previously ( Vaccinia ) Vaccinated Unvaccinated Volunteers</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Vaccinia</mesh_term>
	<mesh_term>Smallpox</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : All drug , medication , therapy , virtue direct pharmacologic action possible drug interaction , could influence intend effect study vaccine mask side effect may concomitantly administer prescription Principal Investigator must document case report form ( CRF ) . Any drug , even aspirin , administer vaccination follow period must document patient 's CRF . Exclusion Criteria Coexisting Condition : Patients follow condition symptom exclude : Failure meet criterion list Inclusion Criteria . Development active eczema skin condition would increase risk secondary vaccinia lesion . Appearance serologic clinical evidence HIV infection prior vaccination . Current evidence clinically active viral infection Mononucleosis , EpsteinBarr Virus , cytomegalovirus may affect immunocompetence . Active overt parasitic , mycobacterial , pyogenic infection affect test designate Inclusion Criteria . Concurrent Medication : Excluded : All drug , medication therapy prescribe Principal Investigator , document case report form ( CRF ) . Any drug , even aspirin , administer vaccination follow period document patient 's CRF . Patients follow exclude : Failure meet criterion list Inclusion Criteria . Appearance serologic clinical evidence HIV infection prior vaccination . Current evidence clinically active viral infection . Active overt parasitic , mycobacterial , pyogenic infection affect test designate Inclusion Criteria . Risk Behavior : Patients agree behave sexually manner minimize risk HIV infection duration study exclude . Patients must : Be HIV seronegative . Have excellent general health . Be unable bear child . Have immediate household contact , sex partner , intimate contact . Be free clinical skin disease . Have sign inform consent . Control subject receive Smallpox vaccine also select inclusion criterion . They may recruit low risk behavior population ; laboratory hospital employee provide service study would normally require Smallpox vaccination ; may heterosexual , homosexual , bisexual . Patients must agree behave sexually manner minimize risk HIV infection duration study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>September 2007</verification_date>
	<keyword>Vaccines , Synthetic</keyword>
	<keyword>Vaccinia Virus</keyword>
	<keyword>Viral Vaccines</keyword>
	<keyword>Smallpox Vaccine</keyword>
	<keyword>HIV-1</keyword>
	<keyword>AIDS Vaccines</keyword>
	<keyword>HIV Seronegativity</keyword>
</DOC>